D. Wheeler

发表

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

Jack T Stapleton, Stuart Haber, David Heckerman, 2010, Science.

Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS.

C. Gibert, D. Abrams, D. Wheeler, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Long-Term Efficacy and Safety of Tipranavir Boosted With Ritonavir in HIV-1-Infected Patients Failing Multiple Protease Inhibitor Regimens: 80-Week Data From a Phase 2 Study

M. Markowitz, H. Valdez, D. Mayers, 2007, Journal of acquired immune deficiency syndromes.

Randomized, controlled trial of caloric supplements in HIV infection

C. Gibert, D. Wheeler, G. Collins, 1999 .

Protein intake is positively associated with body cell mass in weight-stable HIV-infected men.

D. Wheeler, G. Collins, G. Bartsch, 2003, The Journal of nutrition.

Randomized, controlled trial of caloric supplements in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS.

C. Gibert, D. Wheeler, G. Collins, 1999, Journal of acquired immune deficiency syndromes.

Cofilin activation in peripheral CD4 T cells of HIV-1 infected patients: a pilot study

Dongyang Yu, Yuntao Wu, T. Barrett, 2008, Retrovirology.

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

R. Haubrich, M. Kozal, K. Tashima, 2014, The Journal of infectious diseases.

Nutrient Requirements — Research Communication Protein Intake Is Positively Associated with Body Cell Mass in Weight-Stable HIV-Infected Men 1

D. Wheeler, G. Collins, G. Bartsch, 2003 .

Low-Dose Daily Subcutaneous Interleukin-2 in Combination with Highly Active Antiretroviral Therapy in HIV + Patients: A Randomized Controlled Trial

Kendall A. Smith, R. Murphy, C. Cohen, 2000, HIV clinical trials.

Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.

M. King, M. Witt, H. Kessler, 2004, The Journal of infectious diseases.

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.

P. Sax, A. Hsu, D. Kempf, 2002, The Journal of infectious diseases.

The human immunodeficiency virus.

D. Wheeler, 1995, Cutis.

Clinical and demographic features of HIV infection in El Salvador.

R. Cedillos, D. Wheeler, E. García Vázquez, 2003, Revista Panamericana De Salud Publica-pan American Journal of Public Health.

Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.

J. Kilby, I. Patel, J. Lalezari, 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

R. C. Rose, Todd M. Allen, David S. Rubin, 2010, Science.

Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects

G. D. Miralles, I. Patel, E. Dejesus, 2006, AIDS.